Corinne Johnson
Stock Analyst at Goldman Sachs
(3.13)
# 1,233
Out of 5,055 analysts
14
Total ratings
53.85%
Success rate
14.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $10 → $20 | $12.70 | +57.54% | 2 | Sep 16, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $20 → $24 | $16.62 | +44.40% | 2 | Sep 5, 2025 | |
| RNA Avidity Biosciences | Reinstates: Buy | $55 | $70.80 | -22.32% | 2 | Jul 10, 2025 | |
| AVBP ArriVent BioPharma | Reinstates: Buy | $33 | $20.69 | +59.50% | 3 | Jul 10, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $182 | $144.86 | +25.64% | 1 | Jul 10, 2025 | |
| CGON CG Oncology | Upgrades: Buy | $43 → $50 | $41.01 | +21.92% | 3 | May 14, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $23.74 | +110.62% | 1 | Mar 13, 2024 |
Amylyx Pharmaceuticals
Sep 16, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $12.70
Upside: +57.54%
Syndax Pharmaceuticals
Sep 5, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $16.62
Upside: +44.40%
Avidity Biosciences
Jul 10, 2025
Reinstates: Buy
Price Target: $55
Current: $70.80
Upside: -22.32%
ArriVent BioPharma
Jul 10, 2025
Reinstates: Buy
Price Target: $33
Current: $20.69
Upside: +59.50%
Neurocrine Biosciences
Jul 10, 2025
Initiates: Buy
Price Target: $182
Current: $144.86
Upside: +25.64%
CG Oncology
May 14, 2024
Upgrades: Buy
Price Target: $43 → $50
Current: $41.01
Upside: +21.92%
Immunovant
Mar 13, 2024
Initiates: Buy
Price Target: $50
Current: $23.74
Upside: +110.62%